| Pair Name | Garcinol, Cisplatin | ||
| Phytochemical Name | Garcinol (PubChem CID: 5281560 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Garcinol, Cisplatin | |||
| Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in S phase | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CDH13 | hsa1012 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Phosphorylation | PIK3CA | hsa5290 | |
| In Vitro Model | OVCAR-3 | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_0465 |
| Result | Our data demonstrated that garcinol has the potential to be used as an anticancer agent and may synergize the effect of DDP. These actions are most likely through the regulation of the PI3K/AKT and NF-κB pathways. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells. Dose Response. 2020 May 19;18(2):1559325820926732. doi: 10.1177/1559325820926732. | Click |
